The prevalence of Healthcare Effectiveness Data and Information Set (HEDIS) initiation and engagement in treatment among patients with cannabis use disorders in 7 US health systems

References

• National Survey on Drug Use and Health. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.pdf. Published 2017.
   Google Scholar
• Hasin DS, Kerridge BT, Saha TD, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions-III. Ajp. 2016;173(6):588–599.
   Google Scholar
• Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235–1242.
   PubMed Web of Science ®Google Scholar
• Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther. 2015;97(6):607–615.
   PubMed Web of Science ®Google Scholar
• Kerridge BT, Pickering R, Chou P, Saha TD, Hasin DS. DSM-5 cannabis use disorder in the National Epidemiologic Survey on Alcohol and Related Conditions-III: Gender-specific profiles. Addict Behav. 2018;76:52–60.
   PubMed Web of Science ®Google Scholar
• Hasin DS, O’Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834–851.
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance. HEDIS 2015 Technical Specifications. Vol 2. Washington, D.C.: National Committee for Quality Assurance; 2015.
   Google Scholar
• Garnick DW, Lee MT, Horgan C, et al. Lessons from five states: public sector use of the Washington Circle performance measures. J Subst Abuse Treat. 2011;40(3):241–254.
   PubMed Web of Science ®Google Scholar
• Garnick DW, Horgan CM, Chalk M. Performance measures for alcohol and other drug services. Alcohol Res Health. 2006;29(1):19–26.
   PubMedGoogle Scholar
• National Committee for Quality Assurance. The state of health care quality. Available from: http://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2017-table-of-contents/alcohol-treatment. Published 2017.
   Google Scholar
• Harris AH, Bowe T, Finney JW, Humphreys K. HEDIS initiation and engagement quality measures of substance use disorder care: impact of setting and health care specialty. Popul Health Manag. 2009;12(4):191–196.
   PubMed Web of Science ®Google Scholar
• Kerridge BT, Mauro PM, Chou SP, et al. Predictors of treatment utilization and barriers to treatment utilization among individuals with lifetime cannabis use disorder in the United States. Drug Alcohol Depend. 2017;181:223–228.
   PubMed Web of Science ®Google Scholar
• Weisner C, Mertens J, Tam T, Moore C. Factors affecting the initiation of substance abuse treatment in managed care. Addiction. 2001;96(5):705–716.
   PubMed Web of Science ®Google Scholar
• Garnick DW, Lee MT, Horgan CM, Acevedo A. Adapting Washington Circle performance measures for public sector substance abuse treatment systems. J Subst Abuse Treat. 2009;36(3):265–277.
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.
   PubMed Web of Science ®Google Scholar
• D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49(12):1429–1433.
   PubMed Web of Science ®Google Scholar
• Bradley KA, Chavez LJ, Lapham GT, et al. When quality indicators undermine quality: bias in a quality indicator of follow-up for alcohol misuse. Psychiatr Serv. 2013;64(10):1018–1025.
   PubMed Web of Science ®Google Scholar
• van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend. 2013;133(2):776–780.
   PubMed Web of Science ®Google Scholar
• Gates P, Copeland J, Swift W, Martin G. Barriers and facilitators to cannabis treatment. Drug Alcohol Rev. 2012;31(3):311–319.
   PubMed Web of Science ®Google Scholar
• Kleinman LC, Norton EC. What’s the Risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009;44(1):288–302.
   PubMed Web of Science ®Google Scholar
• Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005;6(1):93–109.
   PubMed Web of Science ®Google Scholar
• StataCorp. Stata Statistical Software: Release 15.0 [Computer Program]. College Station, TX: StataCorp LP; 2017.
   Google Scholar
• Harris AH, Humphreys K, Finney JW. Veterans Affairs facility performance on Washington Circle indicators and casemix-adjusted effectiveness. J Subst Abuse Treat 2007;33(4):333–339.
   Web of Science ®Google Scholar
• Bensley KM, Harris AH, Gupta S, et al. Racial/ethnic differences in initiation of and engagement with addictions treatment among patients with alcohol use disorders in the veterans health administration. J Subst Abuse Treat. 2017;73:27–34.
   PubMed Web of Science ®Google Scholar
• MacLean CH, Marnoch E, Sun Z, et al. Quality varies across health insurance marketplace pricing regions. Med Care. 2015;53(7):607–618.
   PubMed Web of Science ®Google Scholar
• Harris AH, Ellerbe L, Phelps TE, et al. Examining the specification validity of the HEDIS quality measures for substance use disorders. J Subst Abuse Treat. 2015;53:16–21.
   PubMed Web of Science ®Google Scholar
• Campbell CI, Bahorik AL, Kline-Simon AH, Satre DD. The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. Drug Alcohol Depend. 2017;178:170–175.
   PubMed Web of Science ®Google Scholar
• Charilaou P, Agnihotri K, Garcia P, Badheka A, Frenia D, Yegneswaran B. Trends of cannabis use disorder in the inpatient: 2002 to 2011. Am J Med. 2017;130(6):678–687. e677.
   PubMed Web of Science ®Google Scholar
• Hayley AC, Stough C, Downey LA. DSM-5 cannabis use disorder, substance use and DSM-5 specific substance-use disorders: Evaluating comorbidity in a population-based sample. Eur Neuropsychopharmacol. 2017;27(8):732–743.
   PubMed Web of Science ®Google Scholar
• John WS, Wu LT. Problem alcohol use and healthcare utilization among persons with cannabis use disorder in the United States. Drug Alcohol Depend. 2017;178:477–484.
   PubMed Web of Science ®Google Scholar
• Bahorik AL, Satre DD, Kline-Simon AH, Weisner CM, Campbell CI. Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated health care system. J Addict Med. 2017;11(1):3–9.
   PubMed Web of Science ®Google Scholar
• Polen MR, Whitlock EP, Wisdom JP, Nygren P, Bougatsos C. Screening in Primary Care Settings for Illicit Drug Use: Staged Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: AHRQ; January 2008.
   Google Scholar
• Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions. Washington, DC: The National Academies Press; 2006.
   Google Scholar
• Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004;291(21):2581–2590.
   PubMed Web of Science ®Google Scholar
• Lapham GT, Lee AK, Caldeiro RM, et al. Frequency of cannabis use among primary care patients in Washington State. J Am Board Fam Med. 2017;30(6):795–805.
   PubMed Web of Science ®Google Scholar
• Bobb JF, Lee AK, Lapham GT, et al. Evaluation of a pilot implementation to integrate alcohol-related care within primary care. Int J Environ Res Public Health 2017;14(9):E1030.
   PubMed Web of Science ®Google Scholar
• Harris AH, Humphreys K, Bowe T, Tiet Q, Finney JW. Does meeting the HEDIS substance abuse treatment engagement criterion predict patient outcomes? J Behav Health Serv Res. 2010;37(1):25–39.
   PubMed Web of Science ®Google Scholar
• Harris AH, Humphreys K, Bowe T, Kivlahan DR, Finney JW. Measuring the quality of substance use disorder treatment: evaluating the validity of the Department of Veterans Affairs continuity of care performance measure. J Subst Abuse Treat. 2009;36(3):294–305.
   PubMed Web of Science ®Google Scholar
• Dunigan R, Acevedo A, Campbell K, et al. Engagement in outpatient substance abuse treatment and employment outcomes. J Behav Health Serv Res. 2014;41(1):20–36.
   PubMed Web of Science ®Google Scholar
• Garnick DW, Horgan CM, Acevedo A, et al. Criminal justice outcomes after engagement in outpatient substance abuse treatment. J Subst Abuse Treat. 2014;46(3):295–305.
   PubMed Web of Science ®Google Scholar
• Acevedo A, Garnick DW, Dunigan R, et al. Performance measures and racial/ethnic disparities in the treatment of substance use disorders. J Stud Alcohol Drugs. 2015;76(1):57–67.
   PubMed Web of Science ®Google Scholar
• Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin North Am. 2012;35(2):309–326.
   PubMed Web of Science ®Google Scholar
• Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014;12(12):CD008940.
   Google Scholar
• Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016;5(5):CD005336.
   Google Scholar